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Summary
Background: Liver failure due to disseminated hepatic secondaries represents a therapeutic dilemma in patients with metastatic breast cancer (MBC). Reduced liver function and non-assessable toxicity are limiting factors in the selection of chemotherapeutic agents. Currently, there is no standard treatment after failure of anthracycline-and taxanebased first-line therapies, although there is a variety of well evaluated drugs such as capecitabine. Case Report: We report on a 45-year-old breast cancer patient with disseminated hepatic metastases. She presented in markedly poor condition, showing substantial ascites and extensive jaundice. Blood chemistry analysis showed increased serum levels of liver enzymes (aspartate aminotransferase 271 U/l, alanine transaminase 101 U/l), bilirubin (7.9 mg/dl), and CA 15-3 (1,459 U/l). We induced a palliative chemotherapy with mitomycin, folinate, and 5-fluorouracil (Mi/Fo/FU). The patient improved impressively after the first cycle of systemic therapy. Liver enzymes stabilized continuously, CA 15-3 returned to normal. The patient was discharged 2 weeks after the treatment start. Chemotherapy was well tolerated under dose escalation, no grade 3/4 toxicity was observed. The progression-free interval was 5 months. Conclusions: A combination therapy with Mi/Fo/FU appears to be a reasonable and tolerable alternative salvage strategy for patients with liver failure due to hepatic breast cancer metastases.
Introduction
Jaundiceduetodisseminatedhepaticmetastasesoftenrepresentsacomplextherapeuticdilemmainthetreatmentofpatients with metastatic breast cancer (MBC). The associated hepatic dysfunction frequently limits the selection of therapeutic agents due to unpredictable toxicity in the setting of alteredhepaticclearance.Atthesametime,thepresenceof liver metastases is in itself considered as a poor prognostic factorforpatientswithMBC.Generally,thesepatientshave beenshowntobelessresponsivetochemotherapywhencompared to patients without hepatic involvement. The median survivalshowsarangeof1-20monthsafterinitialdiagnosis oflivermetastases [1] [2] [3] .Theprincipalaimsofpalliativetreatment in this setting are disease control, relief of symptoms, andimprovementormaintenanceofqualityoflife.Thetwo mostactiveclassesofcytotoxicagentsavailableforthetreatmentofbreastcancerareanthracyclinesandtaxanes.Taxanes areprimarilyeliminatedviathebilesystemandfeces.Therefore,theuseoftaxanesinpatientswithelevatedserumbilirubin or pathologic liver function tests is limited. Anthracyclines are predominantly metabolized by the liver. Impaired liverfunctiondelaystheexcretionandincreasestheaccumulationofthedrugintissueandplasma.Fordoxorubicin,dose reductionsaregenerallynecessarydependingonthebilirubin levels.Bilirubinlevelshigherthan5.0mg/dlareacontraindicationfortheuseofdoxorubicin.Afterthediagnosisofabnormalliverfunction,allchemotherapeuticagentscommonly usedforthetreatmentofMBChavetobeadministeredwith caution.FatalcholestaticliverfailureassociatedwithagemcitabinetherapyinMBChasbeenreported [4] .Inaddition, vinorelbinehastobeadministratedcarefullyastheclearance rate decreases in patients with suppression of liver function [5] .Wereportonthesuccessfultreatmentofajaundicedpatientwithexcessivelivermetastasesofbreastcancerandprogressivehepaticfailureusingacombinedchemotherapywith mitomycin,folinate,and5-fluorouracil(Mi/Fo/FU).
Case Report
A45-year-oldwomanwithahistoryofstageIIbreastcancerpresentedin poorgeneralcondition,withlossofappetite,severefatigue,massivenewly developedascites,distendedabdomen,andextensivejaundice.Symptoms developedrapidlyoveraperiodofonly3-4weeks.Breastcancerhadbeen diagnosed2yearsbeforeandhadbeenclinicallyclassifiedascT2cN1G3M0. Histologically,aninvasiveductalcarcinomacouldbeimmunohistochemicallyconfirmedwithnegativehormonalreceptorstatus(estrogenreceptor score0,progesteronereceptorscore0)andabsenceofanyHER2/neuexpression (HER2/neu score 0). The patient underwent primary systemic therapywith4cyclesofpemetrexed/doxorubicinand4cyclesofdocetaxel withsuboptimalresponse,followedbybreastconservingsurgeryandradiationtherapyofthebreastandregionallymphnodes.ThetumorstageaccordingtothefinalhistopathologywasypT1cypN1a(1/11)G3L0R0M0.
Duringthecurrentadmission,clinicalexaminationrevealedanextensivelyjaundicedpatientwithfindingsasdescribedabove,resultinginan ECOG status 3. Abnormal blood chemistry reports included elevated bilirubin of 7.9 mg/dl and excessively elevated liver enzymes (aspartate aminotransferase(ASAT)271U/l,alaninetransaminase(ALAT)101U/l). Abdominal ultrasound demonstrated multiple disseminated hepatic metastases in both liver lobes. An endoscopic cholangiopancreaticographywasperformedbutdidnotshowanybiliarydilatation.Theclinical performancestatusdecreasedrapidly,andthepatientbecamesomnolent. Ascites was released continuously. In addition, thrombocytopenia complicated the situation, and multiple thrombocyte transfusions had to be administered before starting any further treatment. A combined palliativechemotherapyregimenconsistingofMi/Fo/FUwasstartedat50%of thestandarddoseforthefirst2cycles.Astheperformancestatusofthe patient improved, we escalated the dose up to 100% for the following 3cycles.Chemotherapywasadministeredina3-weekinterval.Thestandard-doseregimenconsistedofmitomycinC(8mg/m 2 intravenously(i.v.)), folinicacid(500mgintotal),and5-fluorouracil(750mg/m 2 i.v.)onday1 plusfolinicacid(500mgintotal)and5-fluorouracil(750mg/m 2 i.v.)on day2.Afterthefirstcycleofchemotherapy,bilirubininitiallyincreased up to 21 mg/dl and then continuously decreased. Six weeks later, the bilirubinserumlevelshadnormalized( fig.1) .Similarfindingswereobserved for the hepatic enzymes ( fig. 2) . Furthermore, CA 15-3 serum levels decreased continuously ( fig. 3) . In parallel, the ascites volume decreased after the second cycle of chemotherapy, and the clinical performanceofthepatientimproved.FourweeksafterstartingMi/Fo/FU, thepatientshowedanECOG1-2andwasabletoparticipateinregular familylifeagain.Allfollowingcyclesofchemotherapywereadministered inanoutpatientsettingwithoutanytherapy-limitingtoxicitiesandwith noneedfordosereduction.Moreover,doseescalationofupto100%was madepossiblebytherapidimprovementofthepatient'sconditionafter thesecondcycleofMi/Fo/FU.Duringtherapy,grade1thrombocytopenia wasobserved,furthermoreamildnauseacorrespondingtoagrade1non-hematologictoxicity.Nograde3or4toxicitywasobserved.
Besidestheimpressiveclinicaltreatmentresponse,theserumlevelsof CA15-3fellrapidlyduringtherapyandfinallynormalized.Theprogression-freeintervalwas5months.Afterthat,CA15-3roseagainandthe patient showed signs of bone marrow depletion consistent with a suspected progressive bone marrow carcinosis so that treatment had to be discontinued. patients with predominant liver metastases with a clinical benefit for the combined chemotherapy with Mi/Fo/FU at a rateof58%;similardataareshownon44patientswithaclini-calbenefitof64% [9] .Abenefitofupto50%andamedian overallsurvivalof12.0monthsunderthetreatmentwithMi/ Fo/FU in patients with impaired hepatic function were reportedbyLoibletal. [7] .Insummary,Mi/Fo/FUseemstobe awelltoleratedregimen.Inourcase,theMi/Fo/FUregimen was used as a salvage treatment for a breast cancer patient withhepaticfailure.Theaimsoftherapyinthepalliativesetting, such as relief of symptoms, improvement of quality of life,possibleprolongationofsurvival,andtherapyadministrationinanoutpatientsetting,couldsuccessfullybeachieved.
Insummary,acombinedchemotherapyregimenwithMi/Fo/ FUappearstobeareasonableandwelltoleratedalternative salvagetreatmentoptionforpatientswithlivermetastasesfrom breastcancer.Theregimenisactiveandfeasiblealsoinpatients showingclinicalsignsofreducedorimpaired hepaticfunction. ThisstrategymayofferanimportantoptionforMBCpatients withreducedperformancestatusand limitedtreatmentoptions duetohepaticimpairmentasa resultoflivermetastases.
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Discussion
SystemictreatmentofMBCwithliverinvolvementandjaundiceoftenisconsideredfutileduetopoorprognosis,limited therapeutic options, and the risk of unpredictable toxicity. Anthracycline-andtaxane-containingregimens,establishedas standard chemotherapy treatment options for the first-line treatment of endocrine-resistant MBC, are metabolized and excreted by the liver and may cause severe side effects in patientswithimpairedliverfunction [6] .Doxorubicinisconsidered to be contraindicated for patients with elevated bilirubinserumlevels,andthedosesofseveralotherdrugshaveto beadjusted.Ontheotherhand,livermetastasesareconsideredtobelessresponsivetochemotherapy [4] .Sofar,thereis noconsensusdefinedforthesystemictreatmentofMBCafter failureofafirst-linetherapy,althoughthereisavarietyofdrugs thathavebeenwellevaluatedsuchascape citabine(table1). Forpatientswithapoorclinicalperformancestatus,theadministrationofchemotherapyhastobe discussedcarefully,as thebenefitcanbeonlymarginal. Patientswithjaundiceareat higherriskfortoxicity,andtreatmentoptionsthereforehave tobeanalyzedindetail.AcombinationchemotherapyconsistingofMi/Fo/FUhasbeenshowntobeactiveandsafeinthe treatmentofpatientswithadvancedlivermetastasessecondary to breast cancer and hepatic dysfunction [7] . Eichbaum etal. [8] reportedaretrospectiveanalysisof76breastcancer
